Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation

Liver Transplantation

Volumn 7, Issue 2, 2001, Pages 113-117

  Ben Ari, Ziv ^a   Mor, Eytan ^b   Shapira, Zaki ^b   Tur Kaspa, Ran ^a  

^a Liver Disease Center   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HEPATECT R; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHIONINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TYROSINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DNA HYBRIDIZATION; DRUG EFFICACY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; PATIENT MONITORING; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECURRENT DISEASE; SEROCONVERSION; VIRUS DETECTION; VIRUS MUTATION; VIRUS STRAIN;

EID: 0035114269     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.21308     Document Type: Article

References (24)

1. Liver transplantation in European patients with the hepatitis B surface antigen
2. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
3. An update on liver transplantation in the US: Recipient characteristics and outcome
4. "Occult" hepatitis B virus as source of infection in liver transplant recipients
5. A preliminary trial of lamivudine for chronic hepatitis B infection
6. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
7. Beneficial effects of lamivudine in recurrent hepatitis B after liver transplantation
8. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
9. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
10. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
11. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after transplantation
12. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity
13. Hepatitis B virus reinfection after orthotopic liver transplantation: Serological and clinical implications
14. Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization
15. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
16. Lack of efficacy of lamivudine for HBV infection after liver transplantation
17. Hepatitis B virus DNA contains a glucocorticoid-responsive element
18. Viral dynamics in hepatitis B virus infection
19. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rate in treatment of recurrence but universal prevention if used as low-dose hepatitis B immune globulin
20. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis
21. Outcome of lamivudine-resistant hepatitis B virus infection in the liver transplant recipient
22. De novo hepatitis B infection after liver transplantation: Source of disease, incidence, and impact
23. Severe clinical course of de novo hepatitis B infection after liver transplantation
24. Lamivudine treatment for acute hepatitis B after transplantation